• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form F-1/A filed by Marex Group plc

    10/22/24 5:21:28 PM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance
    Get the next $MRX alert in real time by email
    F-1/A 1 d835566df1a.htm F-1/A F-1/A

    As filed with the Securities and Exchange Commission on October 22, 2024.

    Registration No. 333-282656

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Amendment No. 1

    to

    FORM F-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Marex Group plc

    (Exact Name of Registrant as Specified in its Charter)

     

     

    Not Applicable

    (Translation of Registrant’s Name into English)

     

     

     

    England and Wales   6200   Not Applicable

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (Primary Standard Industrial Classification

    Code Number)

     

    (I.R.S. Employer

    Identification No.)

    155 Bishopsgate

    London EC2M 3TQ

    United Kingdom

    +44 2076 556000

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

     

    Marex Capital Markets Inc.

    140 East 45th Street, 10th Floor

    New York, New York 10017

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Anna T. Pinedo

    Ryan Castillo

    Mayer Brown LLP

    1221 Avenue of the Americas

    New York, New York 10020

    (212) 506-2275

     

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company ☐

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    †

    The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     


    EXPLANATORY NOTE

    Marex Group plc is filing this Amendment No. 1 (this “Amendment”) to its Registration Statement on Form F-1 (File No. 333-282656) (the “Registration Statement”) as an exhibits-only filing, solely to re-file Exhibit 4.1 which was inadvertently filed without conforming signatures. Accordingly, this Amendment consists only of the cover page, this explanatory note, Part II of the Registration Statement, the signature pages hereto, the amended Exhibit Index and the re-filed Exhibit 4.1. The remainder of the Registration Statement is unchanged and has therefore been omitted.


    PART II

    INFORMATION NOT REQUIRED IN PROSPECTUS

    Item 6. Indemnification of Directors and Officers

    To the extent permitted by law, our amended and restated articles of association provide that the directors and officers of Marex Group plc or any associated company shall be entitled to be indemnified against all losses or liabilities which they incur in execution of their duty in their respective offices. We have entered into deeds of indemnity with each of our executive officers and directors.

    Subject to the provisions of the Companies Act, but without prejudice to any indemnity to which the person concerned may otherwise be entitled, our executive officers and directors (each a “Relevant Officer”) shall have the benefit of a deed of indemnity containing provisions that entitle each Relevant Officer to be indemnified against any liability incurred by or attaching to them (and including all charges, losses, liabilities and damages and all properly incurred costs and expenses incurred by them in relation thereto to the fullest extent permitted by law), provided that our amended and restated articles of association shall not authorize any such person to indemnification to the extent that it would be prohibited or rendered void under the Companies Act or other applicable law, in connection with any proven or alleged negligence, default, breach of duty or breach of trust or otherwise by them in relation to us or any of our associated companies (as defined in section 256 of the Companies Act) thereof, other than: (i) any liability incurred to us or any of our associated companies; (ii) the payment of a fine imposed in any criminal proceeding or a sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature (however arising); (iii) the defense of any criminal proceeding if the Relevant Officer is convicted; (iv) the defense of any civil proceeding brought by us or our associated companies in which judgment is given against the Relevant Officer; (v) any claim which our board of directors determines as arising from the Relevant Officer’s fraud or willful default or which a court has determined as arising from the Relevant Officer’s fraud, willful default, recklessness or gross negligence; and (vi) any application for relief under sections 661(3), 661(4) or 1157 of the Companies Act in which the court refuses to grant relief to the Relevant Officer.

    Subject to the provisions of the Companies Act, pursuant to a deed of indemnity, the Company may provide any Relevant Officer with funds to meet reasonable costs and expenditures incurred or to be incurred by them: (i) in defending any criminal or civil proceedings in connection with any negligence, default, breach of duty or breach of trust or otherwise by them in relation to the Company or an associated company thereof, or (ii) in connection with any application for relief under the Companies Act and otherwise may take any action to enable any such Relevant Officer to avoid incurring such expenditure. Relevant Officers who have received payment from the Company under the relevant indemnification provisions must repay the amount they received in accordance with the Companies Act or in any other circumstances that the Company may prescribe or where the Company has reserved the right to require repayment.

    We provide executive officers’ and directors’ liability insurance for our executive officers and directors against civil liabilities, which they may incur in connection with their activities on behalf of our company. We intend to expand our insurance coverage against such liabilities, including by providing for coverage against liabilities under the Securities Act.

    Any distribution agreement or selling agency agreement that the Company will enter into in connection with offerings of notes being registered hereby will provide that the dealer or agents will agree to indemnify, under certain conditions, us and persons who control our company within the meaning of the Securities Act, against certain liabilities, but only to the extent that such liabilities are caused by information relating to the dealers or agents furnished to us in writing expressly for use in this registration statement and certain other disclosure documents.

     

    II-1


    Insofar as indemnification of liabilities arising under the Securities Act may be permitted to our executive officers, directors or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

    Item 7. Recent Sales of Unregistered Securities

    During the past three years, Marex Group plc issued the following securities without registration under the Securities Act:

     

      •  

    Structured Notes Program: We issued a total of 7,430 Structured Securities during the past three years for a total aggregate offering price of approximately $5,825.3 million. Our Structured Securities are warrants, certificates or notes, including auto-callable, fixed, stability and credit-linked notes with varied terms and were issued as part of our Financial Products business. We used the proceeds of the issuance of the Structured Securities to diversify our sources of funding and for general corporate purposes. Our Structured Securities are customarily purchased by institutional investors.

     

      •  

    EMTN Program: In February 2023, we issued an aggregate principal amount of €300.0 million of 8.375% senior fixed rates notes due February 2, 2028, under our EMTN Program (the proceeds of which were subsequently swapped to USD at an interest rate of SOFR plus 612 basis points). We used the proceeds of the issuance of the 2028 Notes for general corporate purposes, which included the funding of acquisitions. Our 2028 Notes were purchased by institutional investors focused on fixed income debt securities.

     

      •  

    AT1 Securities: In June 2022, we issued an aggregate principal amount of $100.0 million of Additional Tier 1 13.25% fixed rate perpetual subordinated contingent convertible notes for an aggregate offering price, net of issuance costs, of €97.6 million. We used the proceeds of the issuance of the AT1 Securities for general corporate purposes. Our AT1 Securities were purchased by institutional investors focused on fixed income debt securities with a small proportion also purchased by senior management.

    Such securities were issued in reliance on the exemption contained in Section 4(a)(2) of the Securities Act on the basis that the transaction will not involve a public offering. No underwriters were involved in these transactions.

    No underwriter or underwriting discount or commission was involved in any of the transactions set forth in Item 7.

    Item 8. Exhibits

    (a) The Exhibit Index is hereby incorporated herein by reference.

    (b) Financial Statement Schedules.

    All schedules have been omitted because they are not required, are not applicable or the information is otherwise set forth in the Consolidated Financial Statements and related notes thereto.

     

    II-2


    Item 9. Undertakings

    (a) The undersigned Registrant hereby undertakes:

    (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of the securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement; and

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    (2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (4) to file a post-effective amendment to this Registration Statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act need not be furnished, provided, that the Registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements.

    (5) that, for the purpose of determining liability under the Securities Act to any purchaser:

    (i) if the Registrant is relying on Rule 430B:

    (A) each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the Registration Statement as of the date the filed prospectus was deemed part of and included in the Registration Statement; and

    (B) each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information

     

    II-3


    required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the Registration Statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the Registration Statement relating to the securities in the Registration Statement to which the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the Registration Statement or made in a document incorporated or deemed incorporated by reference into the Registration Statement or prospectus that is part of the Registration Statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the Registration Statement or prospectus that was part of the Registration Statement or made in any such document immediately prior to such effective date; or

    (ii) if the Registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the Registration Statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the Registration Statement or made in a document incorporated or deemed incorporated by reference into the Registration Statement or prospectus that is part of the Registration Statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the Registration Statement or prospectus that was part of the Registration Statement or made in any such document immediately prior to such date of first use.

    (6) that, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities, in a primary offering of securities of the undersigned Registrant pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

    (i) any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;

    (ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;

    (iii) the portion of any other free writing prospectus relating to the offering containing material information about the Registrant or its securities provided by or on behalf of the Registrant; and

    (iv) any other communication that is an offer in the offering made by the Registrant to the purchaser.

    (b) For purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    II-4


    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    (d) The undersigned registrant hereby further undertakes that:

    (1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

    (2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    II-5


    EXHIBIT INDEX

     

    Exhibit
    No.
      

    Description

      1.1*    Form of Underwriting Agreement
      1.2*    Form of Selling Agent Agreement
      3.1*    Amended and Restated Articles of Association of the Registrant
      4.1**    Senior Indenture dated as of October 15, 2024 between Marex Group plc and Citibank, N.A. as trustee
      4.2**    Form of Master Global Note (included in 4.1 above)
      5.1*    Opinion of Mayer Brown International LLP, special English counsel to the Registrant, as to the validity of the notes under English law
      5.2*    Opinion of Mayer Brown LLP, special U.S. counsel to the Registrant, as to the legality of the notes under New York law
      8.1*    Opinion of Mayer Brown International LLP as to certain matters under United Kingdom taxation
      8.2*    Opinion of Mayer Brown LLP as to certain matters under United States federal income taxation
     10.1*    Form of Shareholders’ Agreement by and among the Registrant and certain shareholders of the Registrant
     10.2*    Form of Deed of Indemnity
     10.3#*    Marex Group plc Retention Long Term Incentive Plan
     10.4#*    Marex Group plc 2021 Deferred Bonus Plan
     10.5#*    Marex Group plc 2022 Deferred Bonus Plan
     10.6#*    Long-Term Incentive Plan
     10.7*    Revolving Credit Facility by and among Lloyd’s Bank dated March 2014, as amended on June  30, 2023, by and among the Company, Barclays Bank plc, HSBC Bank plc, Bank of China Limited, London Branch, and Industrial and Commercial Bank of China Limited, London Branch
     10.8#*    Form of Marex Group plc Global Omnibus Plan
     10.9#*    Marex Group Limited 2007 Employee Share Purchase Plan, as amended on April 10, 2024
     10.10#*    Form of Marex Group plc Employee Share Purchase Plan
     21.1*    List of subsidiaries of the Registrant
     23.1*    Consent of Deloitte LLP, an independent registered public accounting firm
     23.2*    Consent of Mayer Brown International LLP (included in Exhibit 5.1)
     23.3*    Consent of Mayer Brown LLP (included in Exhibit 5.2)
     23.4*    Consent of Mayer Brown International LLP (included in Exhibit 8.1)
     23.5*    Consent of Mayer Brown LLP (included in Exhibit 8.2)
     24.1*    Power of Attorney (included in signature page to Registration Statement)
     25.1*    Statement of Eligibility and Qualification of Citibank N.A. as Trustee on Form T-1.
    107*    Calculation of Filing Fee Table

     

    *

    Previously filed.

    **

    Filed herewith.

    #

    Indicates management contract or compensatory plan.

     

    II-6


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in London, the United Kingdom on October 22, 2024.

     

    Marex Group plc
    By:  

    /s/ Ian Lowitt

      Name: Ian Lowitt
      Title: Chief Executive Officer

     

    II-7


    Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 1 to the Registration Statement has been signed by the following persons on October 22, 2024 in the capacities indicated:

     

    Name

      

    Title

    /s/ Ian Lowitt

    Ian Lowitt

       Chief Executive Officer and Director
    (principal executive officer)

    /s/ Robert Irvin

    Robert Irvin

      

     

    Chief Financial Officer and Director
    (principal financial officer
    and principal accounting officer)

    *

    Robert Pickering

      

     

    Chair of the Board of Directors

    *

    Madelyn Antoncic

      

     

    Director

    *

    Konstantin Graf von Schweinitz

      

     

    Director

    *

    Sarah Ing

      

     

    Director

    *

    Linda Myers

    *

      

     

    Director

    *

    Roger Nagioff

      

     

    Director

    *

    John W. Pietrowicz

      

     

    Director

    *

    Henry Richards

      

     

    Director

     

    * By:  

    /s/ Robert Irvin

      Name:   Robert Irvin
      Title:   Attorney-in-fact

     

    II-8


    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Marex Group plc has signed this Amendment No. 1 to the Registration Statement on October 22, 2024.

     

      Marex Capital Markets, Inc.
    By:  

    /s/ Michael Conti

      Name:   Michael Conti
      Title:   Head of Legal - North America

     

    II-9

    Get the next $MRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRX

    DatePrice TargetRatingAnalyst
    7/14/2025$54.00Buy
    TD Cowen
    3/10/2025$33.00 → $36.00Buy → Hold
    HSBC Securities
    11/21/2024$33.00Buy
    HSBC Securities
    11/6/2024$34.00Buy
    Citigroup
    5/20/2024$33.00Buy
    Goldman
    5/20/2024$25.00Overweight
    Barclays
    5/20/2024$27.00Overweight
    Piper Sandler
    5/20/2024$27.00Buy
    UBS
    More analyst ratings

    $MRX
    SEC Filings

    View All

    SEC Form 424B3 filed by Marex Group plc

    424B3 - Marex Group plc (0001997464) (Filer)

    1/13/26 2:55:45 PM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 144 filed by Marex Group plc

    144 - Marex Group plc (0001997464) (Subject)

    1/7/26 4:37:04 PM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    SEC Form FWP filed by Marex Group plc

    FWP - Marex Group plc (0001997464) (Subject)

    11/21/25 4:26:39 PM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    $MRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Marex Group plc to acquire equity derivatives market maker Webb Traders

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Marex Group plc ((‘Marex' or the ‘Group', NASDAQ:MRX), the diversified global financial services platform, today announces that it has agreed to acquire European equity derivatives market maker Webb Traders to enhance its market making capabilities. Webb Traders has offices in Amsterdam and Paris and specialises in single stock options market making for European and US mid and large cap equities. The acquisition will bring to Marex a strong, technology led team of market makers, quants and developers, as well as electronic trading capabilities. Webb Traders' trading and risk management philosophy is fully aligned with Marex's approach. The acqu

    2/6/26 7:00:00 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    Marex Group plc completes acquisition of Winterflood and announces agreement to sell Winterflood's custody business

    LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Marex Group plc ((‘Marex' or the ‘Group', NASDAQ:MRX), the diversified global financial services platform, today announces that it has completed the acquisition of UK equity market maker Winterflood Securities ("Winterflood"). Marex further announces it has entered into a conditional agreement to sell Winterflood's custody business, Winterflood Business Services ("WBS"), to Epiris Fund III, advised by Epiris LLP ("Epiris"), a UK private equity firm. WBS provides outsourced dealing, settlement and custody services to a diverse range of clients. The acquisition of Winterflood enhances Marex's existing UK cash equities business, consistent with its s

    12/1/25 7:00:00 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    Marex expands into US Structured Products Market to meet Rising Advisor Demand

    NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (("Marex", NASDAQ:MRX), the diversified global financial services platform, has launched its structured products business in the United States to serve demand from registered investment advisors (RIAs), broker-dealers, and private banks seeking greater issuer and credit diversification. The expansion is led by Scott Kerbel, recently appointed Head of US Distribution for Marex Financial Products. Marex Financial Products brings its established structured products expertise to the US market, drawing on a global business that has issued more than 20,000 structured products. As a globally active non-bank issuer, Marex offers advisors

    11/19/25 7:30:00 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    $MRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Marex Group plc with a new price target

    TD Cowen initiated coverage of Marex Group plc with a rating of Buy and set a new price target of $54.00

    7/14/25 8:52:40 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    Marex Group plc downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Marex Group plc from Buy to Hold and set a new price target of $36.00 from $33.00 previously

    3/10/25 7:56:32 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    HSBC Securities initiated coverage on Marex Group plc with a new price target

    HSBC Securities initiated coverage of Marex Group plc with a rating of Buy and set a new price target of $33.00

    11/21/24 7:35:31 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    $MRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Marex Group plc

    SC 13G - Marex Group plc (0001997464) (Subject)

    11/14/24 5:28:13 PM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Marex Group plc

    SC 13G - Marex Group plc (0001997464) (Subject)

    11/14/24 7:16:40 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Marex Group plc

    SC 13G - Marex Group plc (0001997464) (Subject)

    11/14/24 7:14:47 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    $MRX
    Leadership Updates

    Live Leadership Updates

    View All

    Marex Group plc to acquire European fixed income market maker Valcourt SA

    LONDON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Marex Group plc ((‘Marex' or the ‘Group', NASDAQ:MRX), the diversified global financial services platform, today announces that it has agreed to acquire Valcourt SA ("Valcourt"). Valcourt is a fixed income market maker based in Geneva, Switzerland, specialising in fixed income instruments such as high-yield, subordinated, emerging markets, private, illiquid, and sustainable debt. The acquisition will add 700 clients ranging from banks, independent wealth managers and asset managers. The acquisition is expected to enhance Marex's fixed income business and bring a substantial distribution offering that services the Swiss institutional community, in

    10/22/25 7:00:43 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    Marex Agrees to Acquire Agrinvest Commodities

    LONDON, June 05, 2025 (GLOBE NEWSWIRE) -- Marex Group plc ((‘Marex' or the ‘Group', NASDAQ:MRX), the diversified global financial services platform, today announces that it has agreed to acquire Agrinvest Commodities, a Brazilian agricultural commodities business. This acquisition will expand Marex's operations in the Americas and add new capabilities and clients to diversify earnings. Agrinvest acts as an agent connecting buyers and sellers in physical agricultural markets including corn and soybeans. It also provides its clients with consulting support to understand their hedging options and commercial strategies within these agricultural markets. Acquiring Agrinvest gives Marex physic

    6/5/25 7:00:06 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    Marex Acquires Biofuels Company Dropet

    LONDON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Marex Group Plc (NASDAQ:MRX), the diversified global financial services platform, today announces the completion of its acquisition of Dropet, a Spanish biofuels company, expanding its range of renewables products as it continues to grow its global environmental products business. The acquisition is aligned with Marex's strategy to diversify its business and increase earnings resilience. Dropet offers execution services for both physical and paper biofuels products across Europe, Latin America, the Middle East and Africa. It has more than 18 years' experience in physical ethanol and related biofuel products, as well as exchange-traded ethanol pr

    10/1/24 7:09:16 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    $MRX
    Financials

    Live finance-specific insights

    View All

    Marex Group plc completes acquisition of Winterflood and announces agreement to sell Winterflood's custody business

    LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Marex Group plc ((‘Marex' or the ‘Group', NASDAQ:MRX), the diversified global financial services platform, today announces that it has completed the acquisition of UK equity market maker Winterflood Securities ("Winterflood"). Marex further announces it has entered into a conditional agreement to sell Winterflood's custody business, Winterflood Business Services ("WBS"), to Epiris Fund III, advised by Epiris LLP ("Epiris"), a UK private equity firm. WBS provides outsourced dealing, settlement and custody services to a diverse range of clients. The acquisition of Winterflood enhances Marex's existing UK cash equities business, consistent with its s

    12/1/25 7:00:00 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    Marex Group Plc to Announce Third Quarter 2025 Earnings on November 6, 2025

    NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (NASDAQ:MRX) today announced that it will release its fiscal 2025 third quarter results before market open on Thursday, November 6, 2025. The earnings release and supplementary materials will be available through the "Investors" section of the Marex website at https://ir.marex.com/. A conference call to discuss the results will take place at 9am ET the same day. If you would like to attend the live conference call you can access it here: https://events.q4inc.com/attendee/471691950 About Marex:Marex Group plc (NASDAQ:MRX) is a diversified global financial services platform providing essential liquidity, market access and infrastr

    10/23/25 7:00:00 AM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance

    Marex Group plc to Announce Second Quarter 2025 Results on August 13, 2025

    NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (NASDAQ:MRX), the diversified global financial services platform, today announced that it will release its fiscal 2025 second quarter results before the markets open on Wednesday, August 13. The earnings release and supplementary materials will be available through the "Investors" section of the Marex website at https://ir.marex.com/. A conference call to discuss the results will take place at 9am ET the same day. Analysts and investors who wish to participate in the live conference call can register using the link here: https://edge.media-server.com/mmc/p/gyie6oed About Marex:Marex Group plc (NASDAQ:MRX) is a diversified global

    7/14/25 4:30:00 PM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance